Pay in 4 interest-free payments of $6.05 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
This expedited review reflects the FDA's recognition of the significant unmet medical need in obesity treatment and the potential for orforglipron to expand access to GLP-1 therapy
Peters W et al
FDA news release on Wegovy approval for MASH ESSENCE Study abstract ORFORGLIPRON: A NEW ORAL GLP-1 THERAPY COMING SOON Eli Lilly plans to file for FDA approval of their oral GLP-1 agonist orforglipron by the end of 2025
doi:10.1056/NEJMoa160714 Reserved Perkovic V, Tuttle KR, Rossing P, et al
Invert slowly or swirl gently until everything dissolves
Microbiota-derived imidazole propionic acid (IMP), a histidine metabolite, shows significantly elevated serum levels in HF patients, correlating with left ventricular dysfunction, increased NT-proBNP, and higher 5-year all-cause mortality, suggesting its potential as an independent predictive biomarker (Molinaro et al., 2023)
